12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VX-661: Phase II started

Vertex disclosed in its 4Q11 earnings that it began a Phase II trial to evaluate VX-661 as monotherapy followed by VX-661 plus Kalydeco ivacaftor in CF patients with 2 copies of the F508del...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >